

North Yorkshire & York Area Prescribing Committee

Wednesday 5th June 2024
2pm – 3.30pm, virtual meeting via Microsoft Teams

Present

Name	Job Title	Organisation	Voting Member	Feb 2024	Mar 2024	Apr 2024	May 2024	June 2024
Ken Latta	Head of Medicines Optimisation	North Yorkshire Place	Y	Y	Y	Rachel Ainger	Y	Y
Dr Tim Rider	GP Prescribing Lead	North Yorkshire Place	Y	Y	Y	Y	Y	Y
Chris Ranson	Lead Medicines Management Pharmacist: Commissioning and Formulary – NY&Y	City of York Place	Y	Y	Y	Y	Y	Y
Dr William Ovenden	GP	City of York Place	Y	Y	Y	Y	Y	Y
Kate Woodrow	Chief Pharmacist	Harrogate and District NHS Foundation Trust	Y	Y	Y	Sara Moore	Y	Y
Dr Joanna Cunnington	Consultant and D&T Chair	Harrogate and District NHS Foundation Trust	Y	Y	Y	Y	Y	Y
Stuart Parkes	Chief Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y	Y	Y	Y	Y
Dr Chris Hayes	Consultant and D&T Chair	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y	From 2.50pm	Apols	From 2.22pm	X
Tracy Percival	Formulary Pharmacist	South Tees Hospitals NHS Foundation Trust	Y	Apols	Y	Y	Y	Y
Richard Morris	Deputy Chief Pharmacist	Tees, Esk and Wear Valleys NHS Foundation Trust	Y	Apols	Y	Chris Williams	Until 3pm	From 3pm
Angela Hall	Public Health representative	North Yorkshire County Council	Y	Apols	Kurt Ramsden	Kurt Ramsden	Kurt Ramsden	Kurt Ramsden
Alison Levin	Finance representative	North Yorkshire Place	Y	Jo Horsfall	Apols	Apols	Y	Apols
Hazel Mitford	Lay/patient representative		Y	Y	Y	Apols	Y	Y
Gavin Mankin (Professional Secretary)	Principal Pharmacist Medicines Management	Regional Drug & Therapeutics Centre, Newcastle	N	Y	Y	Y	Y	Y
Laura Angus	Chief Pharmacist at Humber, & North Yorkshire ICS	HNY ICM	N	From 3.15pm	From 3.05pm	X	From 3.11pm	From 3pm
Faisal Majothi	Medicines Optimisation Pharmacist	City of York Place	N	Y	Y	Y	Y	Y
Jane Crewe	Formulary Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	N	Y	Y	Apols	Y	Y
Sara Abbas-Llewelyn	Formulary Pharmacist	Harrogate and District NHS Foundation Trust	N	Apols	Apols	Apols	Apols	Apols
Ian Dean	LPC Representative		N	Y	Apols	Apols	Y	Apols
Dr Jane Raja	LMC Representative		N	Y	Y	Y	Y	Y
Sara Moore	Deputy Chief Pharmacist	Harrogate and District NHS Foundation Trust	N	Apols	From 3.15pm	Y	Apols	Apols

The meeting was quorate with 10 out of 13 currently appointed voting members (or their deputies) in attendance and present throughout.

APC members and attendees were reminded to keep detailed discussions confidential to allow free and full debate to inform unencumbered decision-making. Discretion should be used when discussing meetings with non-attendees, and papers should not be shared without agreement of the chair or professional secretary, to ensure confidentiality is maintained.

The meeting was chaired by Tim Rider.

Part 1

1. **Apologies for absence and quoracy check**

Sara Abbas-Llewelyn, Ian Dean, Sara Moore, Alison Levin

The meeting was quorate.

2. **Declarations of interest**

Declarations of interest:

The Chair reminded subgroup members of their obligation to declare any interest they may have on any issue arising at committee meetings which might conflict with the business of the APC.

Declarations declared by members of the APC are listed in the APC's Register of Interests. The Register is available via the professional secretary.

Declarations of interest from today's meeting:

Nil

3. **Minutes of previous APC & decision summary of meeting held on 1st May 2024**

The minutes of the May 2024 APC were approved as a true and accurate record.

4. **Outcome of items referred to IPMOC**

- TA937: Targeted-release budesonide for treating primary IgA nephropathy – *approved by ICB Executive on 4.6.2024.*
- TA942: Empagliflozin for treating chronic kidney disease – *approved by ICB Executive on 4.6.2024.*
- TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over - *approved by ICB Executive on 4.6.2024.*
- Tirbanibulin ointment – *still awaiting review by Humber APC.*
- NY&Y Iron deficiency pathway and Ferric Maltol: *IPMOC requested review by Humber APC. Humber APC confirmed they do not wish to use. NY&Y APC therefore approved for use locally as within their delegated authority.*

5. **Matters arising not on the agenda & declarations of AOB**

Nil

6. **Action log**

Tirbanibulin

RDTC/CR provided updated cost impact assessment to IPMOC.

NY&Y Modafinil SCG

Final approved version was circulated with May 2024 NY&Y APC Decision Summary. ITEM NOW CLOSED.

NY&Y Hydroxycarbamide SCG

Awaiting amended SCG to come back to APC for approval. RDTC have confirmed the rationale

for for 2 weekly monitoring for patients on high doses.

NY&Y Heart Failure medicines management pathway

Final approved version was circulated with May 2024 NY&Y APC Decision Summary. ITEM NOW CLOSED.

Subcutaneous Levetiracetam in Palliative and End of Life Care (Adults)

Final approved version was circulated with May 2024 NY&Y APC Decision Summary. ITEM NOW CLOSED.

ICB process for IFRs for ICB commissioned drugs

LA has picked this up with the ICB and further information awaited.

Formulary Updates Approved at May 2024 APC

JC/SAL have updated Y&S and Harrogate formularies. ITEM NOW CLOSED.

Outstanding actions from previous APC meetings

Oral minoxidil for androgenic alopecia

Agreed no further action for item for APC. ITEM NOW CLOSED.

Melatonin prescribing paper

NY MO team still to complete paper to submit to future APC outlining the current issues with melatonin prescribing for consideration alongside the request to change the status. APC noted though that this work is starting to progress.

Subcutaneous sodium valproate in palliative care

Second clinical check of guideline by HDFT still needed before can be presented for APC approval.

Proton pump inhibitors in syringe driver guidance (update)

Second clinical check of guideline by HDFT still needed before can be presented for APC approval.

Hydroxychloroquine and chloroquine retinopathy: Recommendations on monitoring 16 December 2020 – updated RCOphth guidelines

Work on adopting national shared care template is ongoing in NY&Y.

Part 2 – Governance

7. System Formulary' – Next Steps – Recommendations

This paper seeks to progress the 'one system formulary' work and separate it in more explicable components. The paper provides a detailed rationale as to why 'one system formulary' is not as simple as the title implies, there is a great deal of complexity to prescribing and formularies. The paper suggests recommendations for the next steps to progress this work.

The next steps recommended which were supported by the APC are:

- Seek to set up a new, one-system area prescribing committee with the correct governance processes for all new applications and any reviews of existing formulary.
- With clinical buy-in, set-up a rolling programme to review the existing separate formularies, as appropriate.
 - Seek to align any new applications, with the advent of the new area prescribing committee.
 - Seek to align the quick wins/easier areas, that are already broadly similar and less contentious.
 - Seek to align the most problematic areas – create queries and pressure for stakeholders, for example, shared care protocols.
 - Seek to align the rest in a chapter-by-chapter, phased approach.

- With clinical buy-in, as part of the area prescribing committee, agree on a reasonable 'adherence' to the formulary, how to support reasonable non-adherence to the formulary and ongoing mechanisms to monitor adherence to the formulary.
- Identify key individuals to take forward the recommendations, in particular the development of one single system wide area prescribing committee.

Part 3 – Mental Health

8. Nil this month.

Part 4 – Formulary issues

9. Appeals against previous APC decisions

Nil this month.

10. Formulary NICE TAs and MHRA Drug Safety Update – April 2024

The drugs in the following TAs to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA963: Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
- TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma

All the above TAs are NHSE-commissioned and would therefore have no cost impact to the ICB.

The following TAs which are NHSE-commissioned were received for information:

- TA966: Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)
- TA968: Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)

The following TAs which are ICB-commissioned were received for information:

- TA969: Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)

Medicines Safety MHRA Drug Safety Update – April 2024

The group noted the drug safety updates for April 2024. The links are to be added to the relevant sections of the formulary.

ACTION:

- **JC/SAL to update the formulary websites.**

11. 30 day TA - NICE TA971 - Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 - May 2024

The drugs in the following TAs published in March 2024 which are ICB commissioned to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 – Remdesivir only recommended by NICE. Noted that no significant cost impact expected. Low use at present and this NICE TA not expected to change use.

ACTION:

- **JC/SAL to update the formulary websites.**

12. Other formulary issues

Nil this month.

13. **New Drug Applications**

Cytisine (cystinicline) 1.5mg Tablets

The APC discussed the application from York and North Yorkshire from Public health.

Requested for smoking cessation and reduction of nicotine craving in those who are willing to stop smoking and to be prescribed only as part of supported quit attempt from local authority specialist stop smoking services. One of a range of treatment options chosen using shared decision-making between clinician and informed patient. Likely to be seen similarly to varenicline as the first line option for patients where nicotine replacement is unsuitable or not preferred.

The following points were raised in discussion:

- Concerns that GPs unfamiliar with this drug would like further information on its safety profile.
- NICE NG209 is still to be updated include cytisine.
- Difference in commissioning position/formulary status between York and North Yorkshire needs sorting for smoking cessation drugs. They are Green in North Yorkshire but Black in City of York on the formulary.

It was agreed not to approve the application until the points above have been addressed.

ACTION:

- **KR to seek further information on safety profile of cytisine.**
- **KR to review difference in commissioning position/formulary status between York and North Yorkshire needs sorting for smoking cessation drugs.**

14. **Compassionate use/free of charge scheme requests**

Nil this month.

Part 5 – Shared Care and Guidelines (non-mental health)

15. **Shared care guidelines for approval**

Nil this month.

16. **HDFT Vitamin B12 Guidelines**

An updated HDFT vitamin B12 guideline was presented to the APC. It has been updated in response to the latest NICE guidance NG239 on vitamin B12.

This guideline will apply only in Harrogate area as HDFT use a different assay to York, and hence cut-offs in Harrogate are different to NICE.

Noted that oral cyanocobalamin not currently listed on the formulary. Use has increased as was used an alternative to IM injections during the COVID pandemic. Agreed to add to formulary and no need for formulary application as low cost and use supported by NICE NG239.

The APC approved the guideline subject to the following changes:

- Define MMA but noted this may be limited by space.
- On left hand side reword “replace” to “replace deficiency with”

ACTION:

- **CR to circulate final approved version.**
- **JC/SAL to update the formulary websites.**

17. **Dapagliflozin & Empagliflozin - Prescribing information for patients with heart failure**

An updated version to reflect the latest NICE TAs was presented to and approved by the APC subject to removing the word “patient” from the title.

Noted that not had feedback from HDFT but they are happy to support on this occasion as document is just supporting information reflecting SPCs/NICE.

ACTION:

- **JC to circulate final approved version.**
- **JC/SAL to update the formulary websites.**

18. Update for Crohn's & Ulcerative colitis pathway

An updated version to reflect NICE TA956 Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over approved at the April 2024 NY&Y APC was presented the APC.

It was agreed to defer approval until feedback from HDFT received.

ACTION:

- **JC to get feedback on updated pathway from HDFT.**

19. Opioid substitution treatment pathway: for patients no longer able to take oral maintenance methadone in last days/weeks of life

The previous guidance was due for review. The guideline has had minor changes to update contact details. A reviewed and updated version was presented to and approved by the APC subject to:

- Updating footer.
- Updating logos to remove CCGs logos and add APC logos instead.
- Ensure refers to Changing Lives/Horizons throughout the document.

ACTION:

- **JC to circulate final approved version.**
- **JC/SAL to update the formulary websites.**

Part 6 – Other items of business

20. Nil this month.

Part 7 – Standing items (for information only)

21. IPMOC minutes – April 2024

Circulated for information.

22. TEWV D&T minutes – since January 2024

Not yet available.

23. York & Scarborough Trust Drug and Therapeutics Committee minutes – March 2024

Circulated for information.

24. Harrogate Trust Medicines and Therapeutics Group minutes – January 2024

Circulated for information.

25. West Yorkshire ICS APC Minutes – since March 2023

Not yet available.

26. Humber APC minutes – April 2024

Circulated for information.

27. Humber APC decisions & recommendations – April 2024

Circulated for information.

28. RDTC Monthly Horizon scanning – May 2024

Circulated for information.

29. NENC Medicines Committee decision Summary – June 2024

Not yet available.

Any Other Business

Puberty blockers in those under 18 years old.

The APC noted the new Government restrictions on the use of puberty suppressing hormones (puberty blockers) from the 3rd June 2024. Agreed that no further action for the APC as these new restrictions have been widely communicated nationally to primary care and community pharmacies.

HNY ICB Shared care protocol: Valproate medicines for patients of child-bearing potential

An updated HNY ICB Shared care protocol: Valproate medicines for patients of child-bearing potential was presented to the APC for approval. It has been updated to reflecting the regulatory changes from January 2024 on the prescribing of oral valproate medicines. Further updates will be required in the future around use in men which new MHRA guidance on use in men becomes available.

The APC did not approve the updated version at this time because:

- Need to ensure all HNY stakeholders including NLAG, TEWV and South Tees have been consulted.
- Require confirmation on whether TEWV will be expected to adopt this for their North Yorkshire patients.
- Version control on first page needs amending as suggests there is a version 2 of the national NHSE SCG which there is not.
- Other monitoring requirements (e.g, LFTs) would be relevant to all patients on valproate not just those of child bearing potential, so why is this SCG just restricted to those of child-bearing potential?
- Are two signatures on ARAF form required only if pregnancy possible? Are two signatures also required if there are compelling reasons that the reproductive risks do not apply?

ACTION:

- **LA to take comments back to authors and to bring an amended version back to a future APC before going to IPMOC for sign off.**

Date and time of next meeting

Wednesday 3rd July 2024, 2pm – 4.30pm, virtual meeting via Microsoft Teams